Targeting AR is a promising therapeutic strategy with the potential to abrogate treatment resistance in glioblastomas, as it is important for the maintenance and proliferation of cancer stem cells, thus fueling interest in the study of AR inhibitors, such as enzalutamide (ENZ), as treatment sensitizers [24]. This evidence concerns the gene AR and glioblastoma.